Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients

Japanese Journal of Clinical Oncology

Volumn 40, Issue 10, 2010, Pages 954-960

  Zhou, Caicun ^a   Ren, Shengxiang ^a   Zhou, Songwen ^a   Zhang, Ling ^a   Su, Cunxia ^a   Zhang, Zengli ^a   Deng, Qinfang ^a   Zhang, Jie ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Chemotherapy; DNA repair gene; Excision repair cross complementing group 1; Non small cell lung cancer; Polymorphisms; X ray repair cross complementing group 3

Indexed keywords

CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM; XRCC3 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CODON; CONFOUNDING VARIABLE; DRUG RESPONSE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PERIPHERAL LYMPHOCYTE; PREDICTION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 77957696698     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq071     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin 2007;57:43-66.
2. Tahara E, Yasui W, Ito H, Harris CC. Recent progress in carcinogenesis, progression and therapy of lung cancer: The 19th Hiroshima Cancer Seminar: The 3rd Three Universities' Consortium International Symposium, November 2009. Jpn J Clin Oncol 2010; doi:10.1093/jjco/hyq031 (Epub ahead of print).
3. Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-24.
4. Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, Celentano E, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001;22:1437-45.
5. Qiao Y, Spitz MR, Shen H, Guo Z, Shete S, Hedayati M, et al. Modulation of repair of ultraviolet damage in the host cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 2002;23:295-9.
6. Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, et al. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Jpn J Clin Oncol 2010;40:286-93.
7. Ford BN, Ruttan CC, Kyle VL, Brackley ME, Glickman BW. Identification of single nucleotide polymorphisms in human DNA repair genes. Carcinogenesis 2000;21:1977-81.
8. Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004;15:1194-203.
9. Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004;44:311-6.
10. Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004;91:344-54.
11. Zhang Zl, Zhou CC, Zhang J, Tang L, Su B. Relationship between polymorphisms of DNA repair gene XRCC3 and susceptibility to lung cancer. Chin J Tuberc Respir Dis 2007;30:1215-20.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
13. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594.
14. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004;10:4939-43.
15. Matakidou A, el Galta R, Webb EL, Rudd MF, Bridle H, et al. GELCAPS Consortium. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet 2007;16:2333-40.
16. Chang PM, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. ERCC1 codon 118 C → T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci 2009;100:278-83.
17. de las Peñas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006;17:668-75.
18. Tripsianes K, Folkers GE, Zheng C, Das D, Grinstead JS, Kaptein R, et al. Analysis of the XPA and ssDNA-binding surfaces on the central domain of human ERCC1 reveals evidence for subfunctionalization. Nucl Acids Res 2007;35:5789-98.
19. Rosell-Costa R, Alberola V, Camps C, Lopez-Vivanco G, Moran T, Etxaniz O, et al. Clinical outcome of gemcitabine (gem)/cisplatin (cis)-vs docetaxel (doc)/cis-treated stage IV non-small cell lung cancer (NSCLC) patients (p) according to X-ray repair cross-complementing group 3 (XRCC3) polymorphism and age. J Clin Oncol 2006;24:7055.
20. Rosell R, Manegold C, Moran T, Garrido P, Blanco R, Lianes P, et al. Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancer. Clin Lung Cancer 2008;9: S76-82.